This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
oncology-screening: Archive
After Golden Cross, Nicolet Bankshares (NIC)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
NICNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings
by Ahan Chakraborty
LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Citizens Financial Services (CZFS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
CZFSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
by Zacks Equity Research
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
ALKSNegative Net Change FOLDPositive Net Change KRYSNegative Net Change IBRXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Erasca Stock Surges 42% in a Week: Here's What You Should Know
by Zacks Equity Research
ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.
ALKSNegative Net Change FOLDPositive Net Change KRYSNegative Net Change ERASPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
After Golden Cross, Adeia (ADEA)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ADEANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BNP Paribas SA (BNPQY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BNPQYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Plains All American Pipeline (PAA) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PAAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Electrolux AB (ELUXY) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ELUXYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MRKRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines